[Federal Register Volume 77, Number 242 (Monday, December 17, 2012)]
[Notices]
[Pages 74670-74671]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-30274]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-D-1145]
Draft Guidance for Industry on Enrichment Strategies for Clinical
Trials to Support Approval of Human Drugs and Biological Products;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Enrichment
Strategies for Clinical Trials to Support Approval of Human Drugs and
Biological Products.'' The purpose of this document is to provide
guidance to industry on enrichment strategies that can be used in
clinical trials intended to support effectiveness and safety claims in
new drug applications (NDAs) and biologics license applications (BLAs).
This document defines several types of enrichment strategies, provides
examples of various potential clinical trial designs, and discusses
potential regulatory considerations when using enrichment strategies in
clinical trials.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by February 15, 2013.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 2201, Silver Spring, MD 20993-0002; or
the Office of Communication, Outreach and Development (HFM-40), Center
for Biologics Evaluation and Research, Food and Drug Administration,
1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448 (1-800-835-
4709 or 301-827-1800), or the Division of Small Manufacturers,
International and Consumer Assistance, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4613, Silver Spring, MD 20993-0002, or fax your
request to 301-847-8149. Send one self-addressed adhesive label to
assist that office in processing your requests. See the SUPPLEMENTARY
INFORMATION section for electronic access to the draft guidance
document.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Robert Temple, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 4212, Silver Spring, MD 20993-0003, 301-
796-2270; or Stephen Ripley, Center for Biologics Evaluation and
Research, Food and Drug Administration, 1401 Rockville Pike, Suite
200N, Rockville, MD 20852-1448, 301-827-6210; or Robert L. Becker,
Center for Device and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5674, Silver
Spring, MD 20993-0003, 301-796-5450.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Enrichment Strategies for Clinical Trials to Support
Approval of Human Drugs and Biological Products.'' This document
provides guidance to industry on enrichment strategies that can be used
in clinical trials intended to support effectiveness and safety claims
in new drug applications (NDAs) and biologics license applications
(BLAs). Similar approaches could be used in clinical trials in earlier
phases of drug development. As part of the reauthorization of the
Prescription Drug User Fee Act (PDUFA IV), FDA committed to certain
performance goals (see letters from the Secretary of Health and Human
Services to the Chairman of the Committee on Health, Education, Labor,
and Pensions of the Senate and the Chairman of the Committee on Energy
and Commerce of the House of Representatives, as set forth in the
[[Page 74671]]
Congressional Record).\1\ This draft guidance addresses one of these
goals with the creation of a guidance document that addresses enriched
trial designs. The guidance defines and discusses three enrichment
strategies: Decreasing heterogeneity, predictive enrichment, and
prognostic enrichment. The guidance also discusses general clinical
trial design considerations, provides examples of potential clinical
trial designs, and discusses regulatory considerations when using
enrichment strategies.
---------------------------------------------------------------------------
\1\ See ``Section A: PDUFA Reauthorization Performance Goals and
Procedures Fiscal Years 2008 Through 2012'' (http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119243.htm).
---------------------------------------------------------------------------
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on clinical
trial designs employing enrichment strategies to support approval of
human drugs and biological products. It does not create or confer any
rights for or on any person and does not operate to bind FDA or the
public. An alternative approach may be used if such approach satisfies
the requirements of the applicable statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm, http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm, or http://www.regulations.gov.
Dated: November 20, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-30274 Filed 12-14-12; 8:45 am]
BILLING CODE 4160-01-P